A Phase II, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Investigate the Efficacy and Safety of RO4602522 Added to Background Alzheimer's Disease Therapy in Patients With Moderate Severity Alzheimer's Disease
Overview
- Phase
- Phase 2
- Intervention
- Placebo
- Conditions
- Alzheimer's Disease
- Sponsor
- Hoffmann-La Roche
- Enrollment
- 542
- Locations
- 142
- Primary Endpoint
- Change From Baseline in Alzheimer's Disease Assessment Scale - Cognitive Behavior Subscale (ADAS-Cog-11) Score at Month 12
- Status
- Completed
- Last Updated
- 8 years ago
Overview
Brief Summary
This Phase II, multicenter, randomized, double-blind, parallel-group, placebo-controlled study will evaluate the efficacy and safety of RO4602522 in participants with moderate severity Alzheimer's disease. Participants who are taking background therapy of acetylcholinesterase inhibitors (AChEI) alone or in combination with memantine for at least 4 months before screening will be randomized to receive either one of two doses of RO4602522 or placebo for 12 months.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Probable Alzheimer disease, based on the National Institute of Neurological and Communicative Disorders and Stroke (NINCDS)/Alzheimer's Disease and Related Disorders Association (ADRDA) and Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition (DSM-IV-TR) criteria
- •Mini-Mental State Exam (MMSE) score at screening between 13 and 20, inclusive
- •Body mass index (BMI) between 18 and 36 kilograms per square meter (kg/m\^2) (inclusive) at screening
- •Modified Hachinski Ischemia Score of less than or equal to (\</=) 4
- •Participants with Cornell Scale for Depression in Dementia (CSDD) scores \</= 13 at screening
- •Receiving treatment with donepezil, rivastigmine, galantamine or any AChEIs in combination with memantine for at least 4 months before screening, with their dose and formulation stabilized at least 3 months before screening. All formulation and dosages are allowed except donezepil 23 mg (alone or in combination)
- •Females of childbearing potential must have a negative pregnancy test and must agree to use effective contraception
- •Generally healthy and ambulatory or ambulatory-aided (i.e., walker or cane)
- •Have a reliable caregiver or some other identified responsible person who has frequent contact with the participant
Exclusion Criteria
- •Any neurological or psychiatric condition that may occur currently or during the course of the study that can impair cognition or functioning that is not associated with Alzheimer's disease
- •Background of mental retardation
- •Uncontrolled behavioral symptoms incompatible with compliance or evaluability
- •Alcohol and/or substance abuse or dependence (DSM-IV-TR) in the past 2 years, except nicotine use which is allowed. However, smokers treated with nicotine replacement therapy or bupropion are excluded
- •Unstable or poorly controlled hypertension as assessed by the investigator regardless of whether or not the participant is taking antihypertensive medications
- •Unstable or clinically significant cardiovascular disease that could be expected to progress, recur, or change during study period to such an extent that it could bias the assessment of the clinical or mental status of the participant
- •Inadequate hepatic, renal or thyroid function
- •Positive for hepatitis B, hepatitis C or human immunodeficiency virus (HIV) infection
- •Poorly controlled diabetes (glycosylated hemoglobin \[HbA1c\] greater than or equal to \[\>/=\] 9 percent at screening)
- •Requiring nursing home care. Participants living in assisted living facilities are allowed if a reliable caregiver is available (see inclusion criteria)
Arms & Interventions
Placebo
Participants will receive placebo as add-on to a background therapy of AChEI (donepezil, rivastigmine, or galantamine) alone or in combination with memantine.
Intervention: Placebo
Placebo
Participants will receive placebo as add-on to a background therapy of AChEI (donepezil, rivastigmine, or galantamine) alone or in combination with memantine.
Intervention: Donepezil
Placebo
Participants will receive placebo as add-on to a background therapy of AChEI (donepezil, rivastigmine, or galantamine) alone or in combination with memantine.
Intervention: Memantine
Placebo
Participants will receive placebo as add-on to a background therapy of AChEI (donepezil, rivastigmine, or galantamine) alone or in combination with memantine.
Intervention: Rivastigmine
Placebo
Participants will receive placebo as add-on to a background therapy of AChEI (donepezil, rivastigmine, or galantamine) alone or in combination with memantine.
Intervention: Galantamine
RO4602522 1 milligram (mg)
Participants will receive RO4602522 1 mg as add-on to a background therapy of AChEI (donepezil, rivastigmine, or galantamine) alone or in combination with memantine.
Intervention: RO4602522
RO4602522 1 milligram (mg)
Participants will receive RO4602522 1 mg as add-on to a background therapy of AChEI (donepezil, rivastigmine, or galantamine) alone or in combination with memantine.
Intervention: Donepezil
RO4602522 1 milligram (mg)
Participants will receive RO4602522 1 mg as add-on to a background therapy of AChEI (donepezil, rivastigmine, or galantamine) alone or in combination with memantine.
Intervention: Memantine
RO4602522 1 milligram (mg)
Participants will receive RO4602522 1 mg as add-on to a background therapy of AChEI (donepezil, rivastigmine, or galantamine) alone or in combination with memantine.
Intervention: Rivastigmine
RO4602522 1 milligram (mg)
Participants will receive RO4602522 1 mg as add-on to a background therapy of AChEI (donepezil, rivastigmine, or galantamine) alone or in combination with memantine.
Intervention: Galantamine
RO4602522 5 mg
Participants will receive RO4602522 5 mg as add-on to a background therapy of AChEI (donepezil, rivastigmine, or galantamine) alone or in combination with memantine.
Intervention: RO4602522
RO4602522 5 mg
Participants will receive RO4602522 5 mg as add-on to a background therapy of AChEI (donepezil, rivastigmine, or galantamine) alone or in combination with memantine.
Intervention: Donepezil
RO4602522 5 mg
Participants will receive RO4602522 5 mg as add-on to a background therapy of AChEI (donepezil, rivastigmine, or galantamine) alone or in combination with memantine.
Intervention: Memantine
RO4602522 5 mg
Participants will receive RO4602522 5 mg as add-on to a background therapy of AChEI (donepezil, rivastigmine, or galantamine) alone or in combination with memantine.
Intervention: Rivastigmine
RO4602522 5 mg
Participants will receive RO4602522 5 mg as add-on to a background therapy of AChEI (donepezil, rivastigmine, or galantamine) alone or in combination with memantine.
Intervention: Galantamine
Outcomes
Primary Outcomes
Change From Baseline in Alzheimer's Disease Assessment Scale - Cognitive Behavior Subscale (ADAS-Cog-11) Score at Month 12
Time Frame: Baseline, Month 12
Secondary Outcomes
- Percentage of Participants with Adverse Events(Baseline up to 13 months)
- Change From Baseline in Columbia Suicide Severity Rating Scale (C-SSRS) Score at 12 months(Baseline, Month 12)
- Percentage of Participants with Change in Lens Opacity Grading(Baseline; Months 6, and 12)
- Maximum Plasma Concentration of RO4602522(Day -1, pre-dose (0 hour) on Days 14, 28, 84, 168, 252, and 364; 1 to 2 hour post dose on Days 14, 84, 252; 2-4 and 5-6 hours post dose on Days 28, 168, and 364)
- Change From Baseline in Alzheimer's Disease Cooperative Study Clinician Global Impression of Change (ADCS-CGIC) Scale Score at 12 months(Baseline, Month 12)
- Percentage of Participants Achieving Response, Defined as an Increase From Baseline of Less Than or Equal to (<=) 4 Points in ADAS-Cog-11(Baseline, Month 12)
- Change From Baseline in Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL) Scale Score at Month 12(Baseline, Month 12)
- Change From Baseline in Behavioral Pathology in Alzheimer's Disease Frequency-Weighted Severity Scale (BEHAVE-AD-FW) Score at Month 12(Baseline, Month 12)
- Percentage of Participants With Worsening in BEHAVE-AD-FW Score(Baseline to Month 12)
- Change From Baseline in Apathy Evaluation Scale (AES) Score at 12 months(Baseline, Month 12)
- Percentage of Participants With Worsening in ADCS-CGIC Score(Baseline to Month 12)
- Change From Baseline in Global Deterioration Scale (GDS) Score at 12 months(Baseline, Month 12)
- Percentage of Participants with Abnormal Visual Acuity Test Results(Baseline, Months 6, and 12)
- Change From Baseline in Michigan Neuropathy Screening Instrument Score(Baseline, Weeks 8, 18, 30, 44, 52, and at the last follow-up visit (12 weeks after last dose, up to 64 weeks))
- Percentage of Participants Receiving Concomitant Medications(Baseline to 13 Months)
- Apparent Total Clearance of the Drug From Plasma After Administration of RO4602522(Day -1, pre-dose (0 hour) on Days 14, 28, 84, 168, 252, and 364; 1 to 2 hour post dose on Days 14, 84, 252; 2-4 and 5-6 hours post dose on Days 28, 168, and 364)
- Area Under the Plasma Concentration-Time Curve of RO4602522(Day -1, pre-dose (0 hour) on Days 14, 28, 84, 168, 252, and 364; 1 to 2 hour post dose on Days 14, 84, 252; 2-4 and 5-6 hours post dose on Days 28, 168, and 364)
- Apparent Volume of Distribution at Steady State after Administration of RO4602522(Day -1, pre-dose (0 hour) on Days 14, 28, 84, 168, 252, and 364; 1 to 2 hour post dose on Days 14, 84, 252; 2-4 and 5-6 hours post dose on Days 28, 168, and 364)